Similar to the 2020 resolution, Novartis AG’s $twenty five million 2016 civil resolution Using the SEC concerned poor sponsorships of HCPs to conferences and inappropriate payments to HCPs to gather “health care data.” The point that Novartis is now struggling with a significantly much larger—and criminal—resolution for comparable miscond